Gene expression signatures add to risk assessment in DLBCL. (A) Estimates of prognostic value added by consideration of expression of two genes (TGS) to the five components of the IPI for predicting risk of death with DLBCL reflect significant improvement in a combined risk model (TGS-IPI) than with clinical indices alone (IPI). NRI, net reclassification improvement.9 NRI was considered both with infinite strata and with 3 predefined risk strata considering 0% to 10%, 11% to 30%, and >30% risk of death within the follow-up interval. Use of alternate microarray probe set summarization methods to estimate expression levels of (B) LMO2 and (C) TNFRSF9 and double logarithm transformation result in significant distortion of the (D) TGS, whether in patients treated with CHOP (black) or RCHOP (red).
